View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

GL Events: 7 directors

Three Directors at GL Events sold 20,000 shares at between 29.090EUR and 30.100EUR. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...

Lagardere S.A.: 1 director

A director at Lagardere S.A. bought 239,973 shares at 24.100EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

Carole Braudeau
  • Carole Braudeau

Credit Morning 06/09/2025

Bernard Arnault is reportedly preparing to exit Lagardère's share capital.|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 09/06/2025

Bernard Arnault s'apprêterait à sortir définitivement du capital de Lagardère|

Geoffroy Michalet
  • Geoffroy Michalet
Geoffroy Michalet
  • Geoffroy Michalet
 PRESS RELEASE

Poxel Announces Positive Results from a Preclinical Study for PXL065, ...

LYON, France--(BUSINESS WIRE)-- Regulatory News: (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the positive top-line results for PXL065 from a preclinical study conducted in a mouse model of hypertrophic cardiomyopathy. PXL065 is a novel, proprietary deuterium-stabilized R-stereoisomer of pioglitazone which is known to reduce inflammation and fibrosis, impro...

 PRESS RELEASE

Poxel annonce les résultats positifs d’une étude préclinique pour le P...

LYON, France--(BUSINESS WIRE)-- Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), société biopharmaceutique au stade clinique développant des traitements innovants pour les maladies chroniques graves à physiopathologie métabolique, dont la stéatohépatite associée à un dysfonctionnement métabolique (MASH) et les maladies métaboliques rares, annonce aujourd'hui les premiers résultats positifs d’une étude préclinique issus d’un modèle murin pour le PXL065 dans le traitement de la cardiomyopathie hypertrophique. Le PXL065 est un nouveau stéréoisomère R de la pioglitazone stabilisé par ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch